NCT05903274View on ClinicalTrials.gov

JSP191 (briquilimab) in Subjects with LR-MDS

PHASE1TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 19, 2023

Primary Completion Date

October 21, 2024

Study Completion Date

October 21, 2024

Conditions
Lower-risk Myelodysplastic Syndrome
Interventions
DRUG

JSP191

Subjects will receive intravenous JSP191

Trial Locations (2)

33021

Memorial Healthcare System, Hollywood

33612

Moffitt Cancer Center, Tampa

Sponsors
All Listed Sponsors
lead

Jasper Therapeutics, Inc.

INDUSTRY